bryostatin 1

a protein kinase C activator; macrocyclic lactone from marine Bryozoan Bugula neritina; RN given refers to (1S*-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-isomer; structure given in first source; activates protein kinase c

Networked: 176 relevant articles (7 outcomes, 45 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Wender, Paul A: 11 articles (01/2020 - 11/2002)
2.	Al-Katib, A M: 8 articles (12/2001 - 02/2000)
3.	Mohammad, R M: 8 articles (12/2001 - 02/2000)
4.	Blumberg, Peter M: 7 articles (12/2016 - 07/2006)
5.	Grant, Steven: 6 articles (10/2006 - 05/2002)
6.	Staveness, Daryl: 5 articles (01/2018 - 10/2014)
7.	Keck, Gary E: 5 articles (12/2016 - 05/2011)
8.	Nakagawa, Yu: 5 articles (04/2016 - 02/2002)
9.	Kedei, Noemi: 5 articles (04/2015 - 05/2011)
10.	Bear, Harry D: 5 articles (11/2013 - 01/2002)

Related Diseases

1.	Neoplasms (Cancer) 10/01/1998 - "SCID mice given bryostatin 1 at 75 microg x kg(-1) x d(-1) for 5 days followed by 30 mg x kg(-1) x d(-1) 2-CdA for 5 days in two cycles, had significantly improved tumor growth delay (P = 0.05). " 04/15/1992 - "Thus, at doses used to treat murine tumors, bryostatin 1 treatment does not affect the clearance of S. " 01/01/2018 - "Therefore, the results of the present study demonstrated that bryostatin 1 inhibited the development and progression of tumors of skin in the mice, through the prevention of inflammation‑inducing processes and the quenching of radicals. " 07/15/2006 - "Bryostatin 1 is currently in clinical trials as a cancer chemotherapeutic agent. " 03/01/1998 - "Phase Ib trial of bryostatin 1 in patients with refractory malignancies."
2.	Leukemia 07/01/2002 - "Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia." 05/16/2011 - "In U937 human leukemia cells, a second system in which PMA and bryostatin 1 have divergent effects, viz. " 07/01/2002 - "Together, these findings demonstrate that bryostatin 1 can be safely administered as a continuous infusion before and after a split course of HiDAC in patients with refractory leukemia, and identify the bryostatin 1 MTD as 50 microg/m(2) when given by this schedule. " 05/01/1996 - "A similar pattern was observed when bryostatin 1 was incubated with leukemia cells in vitro, raising the possibility that the rapid fall in plasma levels results from intracellular uptake and binding. " 07/25/1991 - "In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells."
3.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/01/1998 - "Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies." 10/15/2003 - "Bryostatin 1 is known to exhibit in vitro and in vivo activity against chronic lymphocytic leukemia (CLL) cells by inducing their further maturation into plasma-like cells. " 10/15/2003 - "STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1." 04/01/2000 - "Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report." 10/01/1989 - "Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells."
4.	Neoplasm Metastasis (Metastasis) 01/15/1991 - "There was a clear dose-response effect, with the optimal antimelanoma dose being 100 micrograms/kg/day, but even low doses of bryostatin 1 of 1 micrograms/kg/day resulted in a 53% reduction in the number of metastases. " 06/01/1998 - "We have evaluated the effects of bryostatin 1 on growth of a highly malignant p53-null mouse mammary tumor line, 4T1, and the mechanism by which bryostatin 1 inhibits in vitro growth and in vivo development of tumor and metastases from the orthotopic site. " 01/15/1991 - "These findings indicate that bryostatin 1 may act directly on the B16 melanoma pulmonary metastases. " 06/01/1997 - "The DLN cells were activated with bryostatin 1 and ionomycin (B/I), expanded for 10 days in culture, and transferred to mice with 3-day pulmonary metastases. " 12/01/2016 - "The presence of E-cadherin dynamically regulates PKD1 activation by Bryostatin 1, a potent activator of PKD1, and its substrate phosphorylation specificity, implying a loss of E-cadherin during cancer metastasis could cause the re-distribution PKD1 and re-wiring of PKD1 signaling for distinct functions. "
5.	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 05/01/1998 - "The down-regulation of multidrug resistance (mdr1) gene expression as detected by competitive reverse transcription-PCR and the antitumor activity of bryostatin 1 (Bryo1) are investigated in a newly established cell line from a patient with relapsed diffuse large cell lymphoma (DLCL). " 05/01/1998 - "Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts." 09/01/1995 - "Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma." 06/01/1995 - "The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma." 05/01/2012 - "In addition to primary chronic lymphocytic leukemia cells, bryostatin 1 also sensitizes diffuse large B-cell lymphoma and mantle cell lymphoma cells to BL22 induced apoptosis. "

Related Drugs and Biologics

1.	Protein Kinase C
2.	Antineoplastic Agents (Antineoplastics)
3.	Vincristine (Oncovin)
4.	soblidotin (TZT 1027)
5.	Paclitaxel (Taxol)
6.	Cytotoxins (Cytolysins)
7.	5'-Nucleotidase (5' Nucleotidase)
8.	Phosphotransferases (Kinase)
9.	Deoxycytidine Kinase
10.	bryostatin 7

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Intravenous Infusions
4.	Immunotherapy
5.	Combination Drug Therapy (Combination Chemotherapy)